Forge Biologics, a prominent genetic medicine manufacturer, has teamed up with the California Institute for Regenerative Medicine (CIRM) to bolster the production of adeno-associated adenovirus (AAV) gene therapy programs in California. With $5.5 billion in state funding, CIRM is a leader in regenerative medicine research. Forge will offer its AAV manufacturing expertise to accelerate gene therapy development for CIRM-funded initiatives, expediting clinical trials and commercialization. Forge’s CEO, Timothy J. Miller, expressed enthusiasm for the collaboration, while CIRM’s Senior Director, Shyam Patel, highlighted the partnership’s commitment to advancing regenerative medicine.
Forge Biologics (Forge), a leading manufacturer of genetic medicines, announced today that it has joined the California Institute for Regenerative Medicine’s (CIRM) Industry Resource Partner Program to help advance the manufacturing of adeno-associated adenovirus (AAV) gene therapy programs from the state of California.
With $5.5 billion in funding from the state of California, CIRM is a recognized leader in the development and funding of regenerative medicine clinical trials focused on cell-based and gene therapies.
Forge joins the CIRM Industry Resource Partner Program and will enable accelerated research and cGMP AAV manufacturing to CIRM-funded programs. As a leader in AAV and plasmid manufacturing, Forge will assist CIRM’s partners—which range from industry to academic investigators—in accelerating gene therapy development and manufacturing. Forge’s bespoke platform process and end-to-end CDMO services, including fill-finish, will enable CIRM programs to receive more efficient services and save time getting through the clinical phases of development to reach commercial potential.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“We are enthusiastic about collaborating with the California Institute for Regenerative Medicine to help advance gene therapy programs through our clinically-proven manufacturing processes, which may help CIRM programs more quickly reach clinical trials in a state fulfilling the promise of gene therapy to help patients in need,” said Timothy J. Miller, Ph.D., CEO, President, and Co-Founder of Forge.
Forge specializes in accelerating AAV gene therapy programs at any stage, from preclinical to clinical and commercial manufacturing. All manufacturing is done at the Hearth, Forge’s 200,000 square foot custom-designed cGMP facility in Columbus, Ohio.
“CIRM’s Industry Resource Partner Program aims to create a force-multiplier effect by bringing in industry partners who possess resources, experience, and expertise to accelerate CIRM-funded regenerative medicine research projects,” said Shyam Patel, Ph.D., Senior Director of Business Development and Alliance Management at CIRM. “By agreeing to provide access to its AAV manufacturing services, Forge Biologics joins our collaborative network of partners who share our unwavering commitment to advancing transformative regenerative medicine therapies for patients.”
Source: Biospace
